Abstract Connexin 43 (Cx43) is the predominant protein forming gap junctions and non-
junctional hemichannels in ventricular myocardium, but Cx43 is also localized at the inner …

Background Nusinersen is approved for the treatment of 5q spinal muscular atrophy of all
types and stages in patients of all ages. Although clinical trials have shown improvements in …

We have previously shown that connexin 43 (Cx43) is present in mitochondria, that its
genetic depletion abolishes the protection of ischemia-and diazoxide-induced …

Background Generalised myasthenia gravis is a chronic, unpredictable, and debilitating
autoimmune disease. New treatments for this disease are needed because conventional …

Background Generalised myasthenia gravis is a chronic, unpredictable, and debilitating rare
disease, often accompanied by high treatment burden and with an unmet need for more …

Background Myasthenic crisis (MC) and disease exacerbation in myasthenia gravis (MG)
are associated with significant lethality and continue to impose a high disease burden on …

Background: Nusinersen is an intrathecally administered antisense oligonucleotide (ASO)
and the first approved drug for the treatment of spinal muscular atrophy (SMA). However …

Objective Myasthenia gravis (MG) is the most common autoimmune disorder affecting the
neuromuscular junction. However, evidence shaping treatment decisions, particularly for …

Background Treatment options for cluster headache (CH) include acute, transitional and
prophylactic strategies. We assessed the efficacy and safety of a single occipital nerve block …

Background and objectives In 2020, a wide range of hygiene measures was implemented to
mitigate infections caused by the severe acute respiratory syndrome coronavirus 2 (SARS …